Clinical trials: Liver Transplant Infection
Kidney Failure, Hepatitis C
HCV + to HCV - Kidney Transplant
This is a single center study characterizing the experience of administration of 8 weeks of pan-genotypic DAA therapy in kidney transplantation to prevent the transmission of hepatitis C virus infection from an HCV-positive donor…
- Trial name
- NCT04320290
- Testing
- Direct Acting Antivirals
- Sponsor
- Massachusetts General Hospital
Hepatitis C
Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B
Hepatitis C is the leading cause of liver transplants in the USA. Given that there is a national organ shortage, living donor liver transplantation has became a viable option for patients with end stage liver disease who are not…
- Trial name
- NCT01429155
- Testing
- Interleukin 28B genotype
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Henry Ford Health System
ESRD, Hepatitis C
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
It is well recognized that a subset of patients who contracts Hepatitis C virus (HCV) spontaneously clears the virus. Such individuals are anti-HCV antibody positive, yet HCV RNA PCR negative in the blood.
- Trial name
- NCT02669966
- Testing
- Kidney transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Florida
HBV, Kidney Transplantation
Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
Solid Organ Transplantation (SOT) is made possible by the use of a lifelong immunosuppressive treatment. This treatment limits the response of the immune system, enabling long-term survival of the transplanted organ, but also…
- Conditions
- HBV, Kidney Transplantation, Liver Transplantation
- Trial name
- VITAMIN (NCT06307808)
- Testing
- Tacrolimus, Belatacept
- Where
- France
- Volunteers
- 66 people
- Sponsor
- University Hospital, Grenoble
Hepatitis B Virus Associated Liver Disease
Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation
The purpose of this study is to find the best monthly dose schedule for the new Hepatitis Immune Globulin (Boca HBVIg, a study drug) when used in combination with an antiviral agent Lamivudine after liver transplantation.
- Trial name
- NCT01421212
- Testing
- Hepatitis B Immune Globulin (Boca HBVIg)
- Where
- 11 sites in United States
- Volunteers
- 30 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Liver Diseases, Hepatocellular Cancer
Adult-to-Adult Living Donor Transplant Cohort Study
The study is being conducted for the following reasons: 1. To determine the prevalence, course, and predictors of poor Health Related Quality of Life (HRQOL) outcomes associated with living donor donation. 2.
- Conditions
- Liver Diseases, Hepatocellular Cancer, End Stage Liver Disease, Hepatitis C
- Trial name
- A2ALL-2 (NCT01619475)
- Where
- 9 sites in United States, Canada
- Volunteers
- 1,871 people
- Sponsor
- Arbor Research Collaborative for Health
Hepatitis B Virus, Liver Transplant
To Evaluate the Efficacy and Safety of Tenofovir Alafenamide Conversion in Liver Transplant Patients
This clinical trial aims to confirm the efficacy and safety of Vemlia® tablets (Tenofovir alafenamide) in liver transplant patients with hepatitis B, focusing on their effects on renal function.
- Conditions
- Hepatitis B Virus, Liver Transplant, Renal Insufficiency
- Trial name
- NCT06589518
- Testing
- Tenofovir Alafenamide Citrate
- Volunteers
- 108 people
- Sponsor
- Jongman Kim
Hepatocellular Carcinoma, Hepatoma
HepATocellular Cancer Hcv Therapy Study
Subjects with Hepatitis C Virus (HCV) infection, genotype 1 or 4 and with hepatocellular carcinoma (HCC) and a complete response to HCC therapy will be randomised to immediate or delayed (6 months) HCV therapy with Elbasvir…
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma, Hepatitis C
- Trial name
- HATCHeT (NCT04546802)
- Testing
- Elbasvir / Grazoprevir Oral Tablet
- Sponsor
- Bayside Health
Hepatitis B, ESRD (End Stage Renal Disease)
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
People with kidney failure who are on dialysis have a weaker immune response to the hepatitis B vaccine than healthy people. Even after vaccination, many dialysis patients do not develop enough protection against hepatitis B…
- Conditions
- Hepatitis B, ESRD (End Stage Renal Disease), Kidney Failure, Chronic
- Trial name
- 3v4-HEP-DOSE (NCT07784452)
- Testing
- Recombinant Hepatitis B Vaccine - 3-Dose Schedule, Recombinant Hepatitis B Vaccine - 4-Dose Schedule
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Jinnah Hospital
Liver Transplant Infection, Covid19
Humoral Immunity Against SARS-CoV-2 in Liver Transplanted Patients After COVID-19 in Comparison With Immunocompetent Patients
This is a prospective study analyzing the development of humoral immune response against SARS-Cov-2 in patients with previous Covid19: the aim is to compare the incidence, titration and evolution of IgG an IgM in a prospective…
- Conditions
- Liver Transplant Infection, Covid19, Mortality, Immune Response
- Trial name
- NCT04410471
- Testing
- CLIA of IgG and IgM against SARS-Cov-2
- Where
- 2 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Magdalena Salcedo
Hepatitis C Infection, Viruses
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
The purpose of this study is to test the safety and efficacy of Civacir® to prevent the recurrence of Hepatitis C Virus (HCV) after liver transplant.
- Conditions
- Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human
- Trial name
- NCT01804829
- Testing
- Civacir® 10%
- Where
- 23 sites in United States
- Volunteers
- 80 people
- Sponsor
- Biotest Pharmaceuticals Corporation
Chronic Hepatitis C
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms
Chronic hepatitis C infection (HCV) is a disease that affects worldwide about 170 million people. The previous standard of care therapy of chronic HCV patients consists of pegylated-IFN-α combined with ribavirin, and results in…
- Trial name
- ETIM (NCT01641094)
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Foundation for Liver Research
Hepatitis C Recurrence After Liver Transplant
The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation
Background: Hepatitis C recurrence, which invariably occurs in viremic liver transplant (LT) recipients, associated with accelerated liver fibrosis leading to established graft cirrhosis in 40-20% of patients in 5 years with…
- Trial name
- NCT01707849
- Testing
- EVL arm, MMF arm
- Where
- Spain
- Volunteers
- 18 people
- Sponsor
- Hospital Vall d'Hebron
Cirrhosis, Acute Hepatitis
Development of a Predictive Score for the Risk of Infection in the Immediate Post-liver-transplant Period
Liver transplantation (LT) is the only curative treatment option for patients with severe liver disease. Since 2007, the implementation of the MELD score in liver transplant allocation guidelines has led to a change in the…
- Conditions
- Cirrhosis, Acute Hepatitis, Liver, mHLA-DR
- Trial name
- PREDITH (NCT07647978)
- Testing
- blood sampling, Biocollection
- Where
- 3 sites in France
- Volunteers
- 279 people
- Sponsor
- Hospices Civils de Lyon
Renal Insufficiency
Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction
Renal dysfunction in the context of liver transplantation is a major issue, with difficult patients' management and determining a worsened prognosis.
- Trial name
- ATG_HVH (NCT01453218)
- Testing
- ATeGe-Fresenius
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Hospital Vall d'Hebron
Liver Transplantation, Surgical Site Infection
Surgical Site Infections After Liver Transplantation Based on Perioperative Antibiotics
This study will be to prospectively determine differences in Surgical Site Infection (SSI) if a prolonged course of post-operative antibiotics are used following liver transplantation.
- Trial name
- NCT02717273
- Testing
- standard, extended, liver transplant
- Volunteers
- 102 people
- Sponsor
- University of Virginia
Hepatitis B Infection
HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102
This is a clinical study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.
- Trial name
- NCT03519113
- Testing
- GC1102 80,000 IU, GC1102 100,000 IU, I.V HBIG
- Where
- South Korea
- Volunteers
- 186 people
- Sponsor
- Green Cross Corporation
Transplant-Related Disorder, Hepatitis B Virus Infection
Optimal Timing of Hepatitis B Vaccination After Transplants
The investigators aim to perform a randomized clinical trial to determine the optimal timing of hepatitis B vaccination after hematopoietic cell transplantation (HCT) through evaluating the immunity effect of two different…
- Conditions
- Transplant-Related Disorder, Hepatitis B Virus Infection, Vaccine Reaction
- Trial name
- NCT06888479
- Testing
- hepatitis B vaccine
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Covid19
Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.
Patients undergoing solid organ transplantation randomly selected from those who have received two doses of Spikevax (Moderna) vaccine, provided that a minimum of 8 weeks have elapsed from the second dose to the time of the start…
- Trial name
- REIN-TX (NCT05048940)
- Testing
- Janssen vaccine, Spikevax (Moderna) vaccine
- Where
- Spain
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
Viraemia
CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response
The purpose of this study is to see how well the antibody levels found months to years after patients entered a previous randomised placebo-controlled trial of a glycoprotein B vaccine against cytomegalovirus have persisted and…
- Trial name
- NCT01883206
- Where
- United Kingdom
- Volunteers
- 48 people
- Sponsor
- University College, London